HSV as a vector in vaccine development and gene therapy

Advances in Experimental Medicine and Biology

Volumn 655, Issue , 2009, Pages 118-144

  Marconi, Peggy ^a   Argnani, Rafaela ^b   Epstein, Alberto L ^b   Manservigi, Roberto ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AD 472; ANTIVIRUS AGENT; CYTOKINE; G 207; GANCICLOVIR; HERPES SIMPLEX VACCINE; HERPESVIRUS VECTOR; HSV 1716; ICP 6; INTERFERON; NV 1020; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS; PRODRUG; PROTEIN TYROSINE KINASE; R 3616; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS VACCINE; VACCINE; VIRUS ANTIGEN;

AMPLICON; ARTICLE; CANCER CELL DESTRUCTION; CANCER GENE THERAPY; COLON CANCER; DEFECTIVE VIRUS; DRUG CLASSIFICATION; DRUG DESIGN; DRUG EFFECT; DRUG POTENTIATION; DRUG SAFETY; GENE CONSTRUCT; GENE TRANSFER; GENETIC ENGINEERING; GLIOMA; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; NEUROTROPISM; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; TRANSGENE; VACCINATION; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENOME; VIRUS REPLICATION; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DRUG DEVELOPMENT; GENE THERAPY; GENE VECTOR; GENETICS; METHODOLOGY; NEOPLASM; REVIEW; SIMPLEXVIRUS;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

ANIMALS; ANTIGENS, VIRAL; DNA, VIRAL; DRUG DISCOVERY; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; MODELS, GENETIC; NEOPLASMS; SIMPLEXVIRUS; VACCINATION; VACCINES;

EID: 77955497485     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1132-2_10     Document Type: Article

References (264)

1. Roizman B, Baines J. The diversity and unity of Herpesviridae. Comp Immunol Microbiol Infect Dis 1991; 14(2):63-79.
2. Whitley RJ, Kimberlin DW; Roizman B. Herpes simplex viruses. Clin Infect Dis 1998; 26(3) :541-553; quiz 554-545.
3. Roizman B, Knipe DM. Herpes simplex viruses and their replication. In: Knipe DM, Howley PM, eds, Fields Virology. Vol 2. 2nd ed. Philadelphia: Lippincot, Williams and Wilkins 2001; 2399-2460.
4. Roizman B. HSV gene functions: what have we learned that could be generally applicable to its near and distant cousins? Acta Virol 1999; 43(2-3) :75-80. (Pubitemid 29309500)
5. Subak-Sharpe JH, Dargan DJ. HSV molecular biology: general aspects of herpes simplex virus molecular biology. Virus Genes 1998; 16(3):239-251. (Pubitemid 28282340)
6. Marozin S, Prank U, Sodeik B. Herpes simplex virus type 1 infection of polarized epithelial cells requires microtubules and access to receptorspresent at cell-cell contact sites.J Gen Virol 2004; 85(Pt 4):775-786. (Pubitemid 38489543)
7. Babb R, Huang CC, Aufiero DJ et al. DNA recognition by the herpes simplex virus transacrivaror VP16: a novel DNA-binding structure. Mol Cell Biol 2001 ; 21(14):4700-4712. (Pubitemid 32588251)
8. Jackson SA, DeLuca NA. Relationship of herpes simplex virus genome configuration to productive and persistent infections. Proc Natl Acad Sci USA 2003; 100(13) :7871-7876 . (Pubitemid 36760062)
9. Steiner I, Kennedy PG. Molecular biology of herpes simplex virus type 1 latency in the nervous system. Mol Neurobiol 1993; 7(2) :137-159.
10. Aurelian L HSV-induced apoptosis in herpes encephalitis. Curr Top Microbiol Inununol 2005; 289:79-111. (Pubitemid 40283459)
11. Whitley RJ, Roizman B. Herpes Simplexvirus infections. Lancet. 2001; 357(9267):1513-1518.
12. Daheshia M, Feldman LT, Rouse BT. Herpes simplex virus latency and the immune response. Curr Opin Microbiol 1998; 1(4):430-435. (Pubitemid 128423258)
13. Roizman B, Whitley RJ. The nine ages of herpes simplex virus. Herpes 2001; 8(1) :23-27. (Pubitemid 32290375)
14. Rouse BT. Pathogenesis of the herpesviruses. Lab Anim Sci 1993; 43(1):11-14. (Pubitemid 23075435)
15. Glorioso JC, DeLuca NA. Fink DJ. Development and application of herpes simplex virus vectors for human gene therapy. Annu Rev Microbiol 1995,49, 675-710.
16. Advani SJ, Weichselbaum RR, Whitley RJ et al. Friendly fire: redirecting herpes simplex virus-I for therapeutic applications. Clin Microbiol Infect 2002; 8(9) :551-563. (Pubitemid 35203485)
17. Goins WE Wolfe D, Krisky DM et al. Delivery using herpes simplex virus: an overview. Methods Mol Biol 2004; 246:257-299 .
18. Epstein AL HSV-l-derived recombinant and amplicon vectors for preventiveor therapeutic gene transfer: an overview. Gene Ther 2005; 12 Suppl I:SI53.
19. Lachmann R. Herpes simplex virus-based vectors. Int J Exp Pathol 2004; 85(4) :177-190. (Pubitemid 39120204)
20. Maguire-Zeiss KA, Bowers WJ, Federoff HJ. HSV vector-mediated gene delivery to the central nervous system. Curr Opin Mol Ther 2001; 3(5) :482-490. (Pubitemid 32999001)
21. Glorioso JC, Fink DJ. Herpes vector-mediated gene tran sfer in treatment of diseases of the nervous system. Annu Rev Microbiol 2004; 58:253-271. (Pubitemid 39551987)
22. Markert JM, Gillespie GY, Weichselbaum RR et al. Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol 2000; 10(1):17-30. (Pubitemid 30103131)
23. Niranjan A, Wolfe D, Fellows W et al. Gene transfer to glial tumors using herpes simplex virus. Methods Mol Biol 2004; 246:323-337.
24. Karpoff HM, Kooby D, D'Angelica M et al. Efficient cotransduction of tumors by multiple herpes simplex vectors: implications for tumor vaccine production. Cancer Gene Ther 2000; 7(4):581-588. (Pubitemid 30326894)
25. Toda M, Martuza RL, Kojima H et al. In situ cancer vaccination: an IL-12 defective vector/replication- competent herpes simplex virus combination induces local and systemic anti-tumor activity. J Immunol 1998; 160(9) :4457-4464. (Pubitemid 28217304)
26. Roizman B.Introduction: objectives of herpes simplex virus vaccines seen from a historical perspective. Rev Infect Dis 1991; 13 Suppl 11:S892-894.
27. Kaur A, Sanford HB, Garry D et al. Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology 2007; 357(2) :199-214. (Pubitemid 44830064)
28. Ho DY, Fink SL, Lawrence MS et al. Herpes simplex virus vector system: analysis of its in vivo and in vitro cytopathic effects.J Neurosci Methods 1995; 57(2) :205-215.
29. Roizman B. The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA 1996; 93(21) :11307-11312 . (Pubitemid 26347117)
30. Johnson PA, Miyanohara A, Levine F et al. Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1.J Virol 1992; 66(5) :2952-2965 .
31. Epstein AL, Marconi P, Argnani R et al. HSV-l -derived recombinant and amplicon vectors for gene transfer and gene therapy. Curr Gene Ther 2005 ; 5(5) :445-458. (Pubitemid 41448350)
32. Frenkel N, Singer O. Kwong AD. Minireview: the herpessimplex virus amplicon-a versatile defective virus vector. Gene Ther 1994; 1 Suppll:S40-46.
33. Sena-Esteves M. Saeki Y, Fraefcl C et al.HSV-l amplicon vectors-simplicity and versatility. Mol Ther 2000; 2(1):9-15.
34. Epstein AL. HSV-l-based amplicon vectors: design and applications. Gene Ther 2005; 12 Suppl I:SI54-158.
35. Wang S. Fraefcl C. Breakefield X. HSV-l amplicon vectors. Methods Enzymol 2002; 346:593-603.
36. Halterman MW;Giuliano RE. Bowers WJ et al. Improved HSV-l amplicon packaging usingvirionhost shutoff mutants lacking mRNAse activity. J Gene Med 2006; 8(11):1320-1328. (Pubitemid 44782511)
37. Zhang L, Daikoku T. Ohrake K et al. Establishment of a novel foreign genedelivery system combining an HSV amplicon with an attenuatedreplication- competent virus, HSV-l HF10.J Virol Methods 2006; 137(2):177-183. (Pubitemid 44397157)
38. Sia KC, Wang GY, Ho IA et al. Optimal purification method for Herpes-based viral vectors that confers minimal cytotoxicity for systemic route of vectoradministration. J Virol Methods 2007; 139(2):166-174. (Pubitemid 46074177)
39. Saeki Y, Ichikawa T. Saeki A et al. Herpes simplex virus type 1 DNA amplified as bacterial anificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 1998; 9(18):2787-2794. (Pubitemid 29027021)
40. Saeki Y, Breakefield XO, Chiocca EA. Improved HSV-l amplicon packaging system usingICP27-deleted. oversized HSV-l BACDNA. MethodsMol Med 2003; 76:51-60.
41. Logvinoff C, Epstein AL. Anovel approach forherpes simplex virus type 1amplicon vector production. using the Cre-loxPrecombination system to remove helpervirus. Hum Gene Ther 2001; 12(2):161-167. (Pubitemid 32095454)
42. Marconi P.Krisky D, Oligino T et al. Replication-defective herpessimplex virusvectors for genetransfer in vivo. Proc Natl Acad Sci USA 1996; 93(21):11319-11320. (Pubitemid 26347119)
43. Krisky DM, Marconi PC, Oligino TJ et al. Development of herpessimplex virus replication-defective multigene vectors for combination genetherapy applications. Gene Ther 1998; 5(11):1517-1530. (Pubitemid 28517379)
44. Wu N, Watkins SC. Schaffer PAet al. Prolonged gene expression and cell survival afrerinfection by a herpessimplex virusmutant defective in the immediate-early genes encodingICP4. ICP27 and ICP22. J Virol 1996; 70(9):6358-6369. (Pubitemid 26266856)
45. DeLuca NA. Schaffer PA. Activation of immediate-early. early and late promoters by temperaturesensitive and wild-type forms of herpes simplex virus type 1 protein ICP4. Mol Cell Biol 1985; 5(8):1997-1208.
46. DeLuca NA. Schaffer PA. Physical and functional domains of the herpessimplex virus transcriptional regulatory protein ICP4. J Virol 1988; 62(3):732-743. (Pubitemid 18068627)
47. Sze P,Herman RC. The herpes simplex virus type 1 ICP6 geneis regulated by a 'leaky' early promoter. Virus Res 1992; 26(2):141-152.
48. Everett RD. ICPO, a regulator of herpes simplex virus during lyticand latent infection. Bioessays 2000; 22(8):761-770. (Pubitemid 30613308)
49. Prod'hon C. Machuca I. Berthomme H et al. Characterization of regulatory functions of the HSV-1 immediate-early protein ICP22. Virology 1996; 226(2):393-402. (Pubitemid 27025819)
50. Long MC. Leong V. Schaffer PA et al. ICP22 and the UL13 protein kinase arc both required for herpes simplex virus-induced modification of the large subunit of RNA polymerase II. J Virol 1999; 73(7):5593-5604. (Pubitemid 29274843)
51. Karo A. Yamamoto M. Ohno T et al. Identification of proteins phosphorylated directly by the Us3 protein kinase encodedby herpes simplex virus 1.J Virol 2005; 79(14):9325-9331. (Pubitemid 40934845)
52. Purves FC, Ogle WO, Roizman B. Processing of the herpes simplex virus regulatory protein alpha 22 mediated by the UL13 protein kinase determines the accumulation of a subset of alpha and gamma mRNAs and proteins in infected cells. Proc Natl Acad Sci USA 1993; 90(14):6701-6705. (Pubitemid 23207281)
53. Ogle WO, Ng TI, Carter KL, et al.The UL13 protein kinase and the infected cell type are determinants of pomranslational modification of ICPO. Virology 1997; 235(2):406-413. (Pubitemid 27394354)
54. Hill A. Jugovic P, York I et al.. Herpes Simplex virus turns off the TAP to evade host immunity. Nature 1995; 375(6530):411-415.
55. Tomazin R, Hill AB,Jugovic P et al. Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBOJ 1996; 15(13):3256-3266. (Pubitemid 26231931)
56. Galocha B, Hill A. Barnett BC et al.Theactive site of ICP47, a herpes simplex virus-encoded inhibitor of the major histocompatibility complex (MHC)-encoded peptide transporter associated with antigen processing (TAP), maps to the NH2-terminal 35 residues. J Exp Med 1997; 185(9):1565-1572. (Pubitemid 27203253)
57. Samaniego LA. Neiderhiser L. DeLuca NA. Persistence and expression of the herpes simplex virus genomein the absence of immediate-early proteins. J Virol 1998; 72(4):3307-3320. (Pubitemid 28175576)
58. Samaniego LA. Wu N, DeLuca NA. The herpes simplex virus immediate-early protein lCPO affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol 1997; 71(6):4614-4625. (Pubitemid 27204154)
59. Krisky DM, Marconi PC. Oligino T et al. Rapid method for construction of recombinant HSV gene transfer vectors. Gene Ther 1997; 4(10):1l20-1125.
60. Wood MJ. ByrnesAP. Kaplin MG et al. Specific patterns of defective HSV-l gene transfer in the adult central nervous system: implications for gene targeting. Exp Neurol 1994; 130(1):127-140.
61. Kaplin MG. Makimura H. Defective viral vectors as agents for gene transfer in the nervous system. J Neurosci Methods 1997: 71(1):125-132. (Pubitemid 27145778)
62. Kaplin MG. Pfaff DW. Viral Vectors for Gene Delivery and Expression in the CNS. Methods 1996: 10(3):343-350. (Pubitemid 26391933)
63. Krisky DM, Wolfe D. Goins WF et al. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther 1998; 5(12):1593-1603. (Pubitemid 29008329)
64. Todo T. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Hum Cell 2002; 15(3):151-159.
65. Hu JC. Coffin RS. Oncolytic herpes simplex virusfor tumor therapy. Im Rev Neurobiol 2003: 55:165-184. (Pubitemid 44804465)
66. Post DE. Fulci G. Chiocca EA et al. Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther 2004: 4(1):41-51. (Pubitemid 38854945)
67. Samady L, Costigliola E. MacCormac L et al. Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immuno therapy.J Virol 2003: 77(6):3768-3776. (Pubitemid 36297295)
68. Roizman B. Markovitz N. Herpes simplexvirus virulence: the functions of the gamma (1)34.5 gene. J Neurovirol 1997; 3(Suppl 1):S1-2. (Pubitemid 27232285)
69. Daikoku T, Yamamoto N. Maeno K et al. Role of viral ribonucleotide reductase in the increase of dTTP pool size in herpes simplex virus-infectedVero cells. J Gen Virol 1991: 72 ( Pt 6):1441-1444.
70. Becker Y.Tavor E. Asher Y et al. Effect of herpes simplex virus type-I UL41 gene on the stability of mRNA from the cellular genes: beta-actin. fibronecnn, glucose transporter-I and docking protein and on virus intraperitoneal pathogenicity to newborn mice. Virus Genes 1993; 7(2):133-143. (Pubitemid 23199720)
71. Strelow LI. Leib DA. Role of the virion host shutoff (vhs) of herpes simplexvirus type I in latency and pathogenesis.J Virol 1995; 69(11):6779-6786.
72. Barzilai A. Zivony-Elbom I. Sarid R et al. The herpes simplex virus type I vhs-UL41 gene secures viral replication by temporarily evading apoptotic cellular response to infection: Vhs-UL41 activity might require interactions with elements of cellular mRNA degradation machinery. J Virol 2006; 80(1):505-513.
73. Broberg EK, Hukkanen V. Immune response to herpes simplex virus and gamma134.5 deleted HSV vectors. Curr Gene Ther 2005; 5(5):523-530. (Pubitemid 41448356)
74. Talloczy Z. Virgin HWt. Levine B. PKR-dependent autophagic degradation of herpes simplex virus type 1. Autophagy 2006; 2(1):24-29.
75. Cheng G. Feng Z. He B. Herpes simplex virus I infection activates the endoplasmic reticulum resident kinase PERK and mediates elF-2alpha dephosphorylation by the gamma(1)34.5 protein. J Virol 2005; 79(3):1379-1388. (Pubitemid 40459085)
76. Shah AC. Benos D. Gillespie GY et al. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas.J Neurooncol 2003; 65(3):203-226. (Pubitemid 37526814)
77. Mullen JT. Tanabe KK. Viral oncolysis. Oncologist 2002; 7(2):106-119. (Pubitemid 34438539)
78. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002; 2(12):938-950. (Pubitemid 37328895)
79. Stricklen PK. Nelson RD, Kohan DE. Site-specific recombination using an epirope tagged bacteriophage PI Cre recornbinase. Gene 1998; 215(2):415-423. (Pubitemid 28382944)
80. Kong Y. Yang T. Geller AI. An efficient in vivo recombination cloning procedure for modifying and combining HSV-l cosmids. J Virol Methods 1999; 80(2):129-136. (Pubitemid 29341609)
81. Stavropoulos TA. Srrarhdee CA. An enhanced packaging system for helper-dependent herpes simplex virus vectors.J Virol 1998; 72(9):7137-7143. (Pubitemid 28377842)
82. Zhang X. O'Shea H. Entwisle C et al. An efficientselection system for packaging herpes simplex virus amplicons.J Gen Virol 1998; 79 ( Pt 1):125-131. (Pubitemid 28039310)
83. Horie K. Nishiguchi S. Maeda S et al. Structures of replacement vectors for efficient gene targeting. J Biochern (Tokyo) 1994: 115(3):477-485. (Pubitemid 24096459)
84. Gierasch WW, Zimmerman DL. Ward SL et al. Construction and characterization of bacterial artificial chromosomes containing HSV-1 strains 17 and KOS. J Virol Methods 2006; 135(2):197-206. (Pubitemid 43902981)
85. Schmeisser F. Weir JP. Incorporation of a lambda phage recombination system and EGFP detection to simplify mutagenesis of Herpes simplex virus bacterial artificial chromosomes. BMC Biocechnol 2007; 7:22.
86. Tanaka M, Kagawa H. Yamanashi Y et al. Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type I: viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo. J Virol 2003; 77(2):1382-1391. (Pubitemid 36055560)
87. Terada K, Wakimoto H, Tyminski E ec al. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse rumor models. Gene Ther 2006; 13(8):705-714.
88. Kuroda T, Marruza RL, Todo T et al. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biorcchnol 2006; 6:40.
89. Koelle OM, Corey L Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003; 16(1):96-113. (Pubitemid 36114709)
90. Stanberry LR. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 2004; 11 Suppl 3:161A-169A . (Pubitemid 39145462)
91. Lauterbach H, Kerksiek KM, Busch DH et al. Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1. J Virol 2004; 78(8) :4020-4028. (Pubitemid 38437208)
92. Watanabe O, Brockman MA, Ndung'u T et al.Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector. Virology 2007; 357(2) :186-198. (Pubitemid 44821300)
93. Santos K, Duke CM, Dewhurst S. Amplicons as vaccine vectors. Curr Gene Ther 2006; 6(3) :383-392. (Pubitemid 43905454)
94. Suter M, Lew AM, Grob P et al. BAC-VAC, a novel generation of (DNA) vaccines: A bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1. Proc Nacl Acad Sci USA 1999; 96(22) :12697-12702. (Pubitemid 29513565)
95. Krause PR, Straus SE. Herpesvirus vaccines. Development, controversies and applications. Infect Dis Clin North Am 1999; 13(1):61-81, vi.
96. Hocknell PK, Wiley RD, Wang X et al. Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type L-derived amplicons results in potent, specific and durable cellular and humoral immune responses. J Virol 2002; 76(11) :5565-5580. (Pubitemid 34517907)
97. Brehm M, Samaniego LA, Bonneau RH et al. Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, lCP27, ICP22 and ICPO. Virology 1999; 256(2):258-269. (Pubitemid 29393361)
98. Brockman MA, Knipe OM. Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J Virol 2002; 76(8):3678-3687. (Pubitemid 34250532)
99. Lauterbach H, Ried C, Epstein AL et al. Reduced immune responses alter vaccination with a recombinant herpes simplex virus type 1 vector in the presence of anti-viral immunity. J Gen Virol 2005; 86(Pt 9):2401-2410 . (Pubitemid 41167587)
100. Sena-Esteves M, Hampl JA, Camp SM et al. Generation of stable retrovirus packaging cell lines alter transduction with herpes simplex virus hybrid amplicon vectors. J Gene Med 2002; 4(3) :229-239. (Pubitemid 40268359)
101. Savard N, Cosset FL, Epstein AL. Defective herpes simplex virus type 1 vectors harboring gag, pol and env genes can be used to rescue defective retrovirus vectors. J Virol 1997; 71(5) :4111-4117 . (Pubitemid 27172430)
102. Hong Z, Ferrari E, Wright-Minogue J et al. Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system. J Virol 1996; 70(7) :4261-4268 . (Pubitemid 26187426)
103. Tsitoura E, Lucas M, Revel-Guyot V et al. Expression of hepatitis C virus envelope glycoproteins by herpes simplex virus type 1-based amplicon vectors. J Gen Virol 2002; 83(Pt 3):561-566. (Pubitemid 34183001)
104. Tsitoura E, Georgopoulou U, Mavromara P. HSV-1 based amplicon vectors as an alternative system for the expression of functional HCV proteins . Curr Gene Ther 2006; 6(3):393-398. (Pubitemid 43905455)
105. Zager JS, Delman KA, Malhotra S et al. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Mol Med 2001; 7(8) :561-568. (Pubitemid 33701962)
106. D'Angelica M, KarpoffH, Halterman Met al. In vivo interleukin-2 gene therapy of established rumors with herpes simplex amplicon vectors. Cancer Immunol Immunother 1999; 47(5) :265-271. (Pubitemid 29062313)
107. Hoshino Y,Dalai SK, Wang K et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 2005; 79(1) :410-418. (Pubitemid 39648394)
108. Da Costa XJ, Morrison LA, Knipe OM. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. Virology 2001; 288(2) :256-263. (Pubitemid 32929905)
109. McLean CS, Errurk M, Jennings Ret al. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis 1994: 170(5) :1100-1109. (Pubitemid 24328611)
110. Us D. [Herpes simplex virusvaccine studies: from past to present J. Mikro biyol Bul 2006; 40(4):413-433.
111. Da Costa X, Kramer MF, Zhu J et al. Consrruction, phenotypic analysisand immunogenicity of a UL51 UL29 double deletion mutant of herpes simplex virus 2. J Virol 2000; 74(17):7963-7971. (Pubitemid 30641640)
112. Ali SA. McLean CS. Boursnell ME et al. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes. Cancer Res 2000; 60(6) :1663-1670. (Pubitemid 30183439)
113. Bozac A. Berro E. Vasquez F et al. Expression of human immunodeficiency virus type 1 tat from a replication -deficient herpes simplex type 1 vector induces antigen-specific T-cell responses. Vaccine 2006; 24(49-50) :7148-7158 . (Pubitemid 46107201)
114. Fiorentini S. Becker PD. Marini E et al. HIV-l matrix protein p 17 modulates in vivo preactivated murine T-cell response and enhances the induction of systemic and mucosal immunity against intranasally co-administered antigens. Viral Immunol 2006; 19(2):177-188. (Pubitemid 44050316)
115. Murphy CG. Lucas WT. Means RE et al. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.J Virol 2000; 74(17):7745-7754 . (Pubitemid 30641618)
116. Chou J. Kern ER. Whirley RJ et al. Mapping of herpes simplex virus-I neurovirulence to gamma 134.5. a gene nonessential for growth in culture . Science 1990; 250(4985) :1262-1266. (Pubitemid 120031840)
117. Meignier B. Martin B. Whitley RJ et al. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus).J Infect Dis 1990; 162(2):313-321. (Pubitemid 20239942)
118. Spector FC. Kern ER. Palmer J et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs.J Infect Dis 1998; 177(5) :1143-1154. (Pubitemid 28194250)
119. Prichard MN. Kaiwar Rvjackman WT et al. Evaluation of AD4n. a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 2005; 23(46-47) :5424-5431. (Pubitemid 41579315)
120. Bernstein DI. Ireland J. Bourne N. Pathogenesis of acyclovir-resistant herpes simplex type 2 isolates in animal models of genital herpes: models for anti-viral evaluations. Antiviral Res 2000; 47(3) :159-169.
121. Bernstein DI. Stanberry LR. Herpes simplex virus vaccines. Vaccine 1999; 17(13-14) :1681-1689. (Pubitemid 29138901)
122. Walker J. Leib DA. Protection from primary infection and establishment oflatency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function . Vaccine 1998; 16(1):1-5. (Pubitemid 27504796)
123. Aurelian L. Kokuba H. Smith CC. Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICPIO). Vaccine 1999; 17(15-16): 1951-1963. (Pubitemid 29172365)
124. Garrido JJ. Alonso MT. Lim F et al. Defining responsiveness of avian cochlear neurons to brain-derived neurotrophic factor and nerve growth factor by HSV-1-mediated gene transfer. J Neurochern 1998; 70(6):2336-2346. (Pubitemid 28252359)
125. Pakzaban P. Geller AI. Isacson O. Effect of exogenous nerve growth factor on neurotoxicity of and neuronal gene delivery by a herpes simplex amplicon vector in the rat brain . Hum Gene Ther 1994; 5(8) :987-995. (Pubitemid 24304760)
126. Geschwind MD. Hartnick CJ. Liu W et al. Defective HSV-1 vector expressing BDNF in auditory ganglia elicits neurite outgrowth: model for treatment of neuron loss following cochlear degeneration. Hum Gene Ther 1996; 7(2) :173-182. (Pubitemid 26044836)
127. Sortwell CE,Bowers WJ. Counts SE et al. Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival. Brain Res 2007; 1134(1) :33-44. (Pubitemid 46135538)
128. Antonawich FJ. Federoff HJ. Davis JN. BCL-2 transduction. using a herpes simplex virus amplicon, protects hippocampal neurons from transient global ischemia. Exp Neurol 1999; 156(1):130-137. (Pubitemid 29152990)
129. Hoehn B. Ringer TM . Xu L et al. Overexpression of Hspn after induction of experimental stroke protects neurons from ischemic damage.J Cereb Blood Flow Merab 2001; 21(11) :1303-1309 . (Pubitemid 33130942)
130. Wang H. Cheng E. Brooke S et al. Over-expression of anti-oxidant enzymes protects cultured hippocampal and cortical neurons from necrotic insults. J Neurochem 2003; 87(6) :1527-1534. (Pubitemid 38020586)
131. Adrover MF. Guyot-Revel V. Cheli VT et al. Hippocampal infection with HSV-1-derived vectors expressing an NMDARI antisense modifies behavior. Genes Brain Behav 2003; 2(2) :103-113. (Pubitemid 36717655)
132. Chell VT. Adrover MF. BlancoC et al. Gene transfer of NMDARI subunit sequences to the rat CNS using herpes simplex virus vectors interfered with habituation . Cell Mol Neurobiol 2002; 22(3):303-314. (Pubitemid 35364888)
133. Neillj'C, Sarkisian MR. Wang Yet al. Enhanced auditory reversal learning by genetic activation of protein kinase C in small groups of rat hippocampal neurons. Brain Res Mol Brain Res 2001; 93(2):127-136. (Pubitemid 32925173)
134. Brooks al. Cory-Slechta DA. Bowers WJ et al. Enhanced learning in mice parallels vector-mediated nerve growth factor expression in hippocampus. Hum Gene Ther 2000; 11(17):2341-2352 .
135. Sun M. Zhang GR. Kong L et al. Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector. Hum Gene Ther 2003; 14(5):415-424. (Pubitemid 36403534)
136. Sun M. Kong L. Wang X et al. Compari son of the capability of GDNE BDNF, or both, to protect nigrostriaeal neurons in a rat model of Parkinson's disease. Brain Res 2005; 1052(2) :119-129. (Pubitemid 41116769)
137. Geller al. Yu L. Wang Y et al. Helper virus-free herpes simplex virus-I plasmid vectors for gene therapy of Parkinsons disease and oth er neurological disorders. Exp Neurol 1997; 144(1):98-102. (Pubitemid 27149609)
138. Geller AI, During MJ, Oh YJ et al An HSV-1 vector expressing tyrosine hydroxylasecauses produerion and release of L-dopa from cultured rat striatal cells. J Neurochern 1995; 64(2) :487-496.
139. During MJ, Naegele JR. O'Malley KL et al. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 1994; 266(5189):1399-1403.
140. Fraefel C, Mendes-Madeira A. Mabon O et al. In vivo gene transfer to the rat retina using herpes simplex virus type 1 (HSV-1)-based amplicon vecto rs. Gene Ther 2005; 12(16):1283-1288 . (Pubitemid 41195119)
141. Wade-Martins R, Smith ER. Tyminski E et al.An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol 2001 ; 19(11):1067-1070. (Pubitemid 33041892)
142. Inoue R, Moghaddam KA, Ranasinghe M et al. Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. Gene Ther 2004; 11(15):1195-1204. (Pubitemid 39136783)
143. Xing W; Baylink D, Kesavan C et al HSV-1 amplicon-mediatcd transfer of 128-kb BMP-2 genomic locus stimulates osteoblast differentiation in vitro. Biochem Biophys Res Common 2004; 319(3):781-786. (Pubitemid 38739389)
144. Burton EA, Fink DJ, Glorioso Jc. Replication-defeerive genomic HSV gene therapy veerors: design production and CNS applications. Curr Opin Mol Ther 2005; 7(4):326-336. (Pubitemid 41103052)
145. Frampton AR Jr. Goins WF, Nakano et al. HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther 2005; 12(11):891-901. (Pubitemid 40852207)
146. Simonato M, Manservigi R, Marconi P et al. Gene transfer into neurones for the molecular analysis of behaviour: focus on herpes simplex vectors. Trends Neurosci 2000; 23(5) :183-190. (Pubitemid 30236175)
147. Simonato M. Marconi P, Glorioso Jet al. Molecular analysis of behavior by gene transfer into neurons with herpes simplex vectors. Brain Res 1999; 835(1) :37-45. (Pubitemid 29336548)
148. Burton EA, Glorioso JC. Fink DJ. Gene therapy progress and prospects: Parkinson's disease. Gene Ther 2003; 10(20):1721-1727. (Pubitemid 37121043)
149. Yamada M, Oligino T. Mara M et al. Herpes simplex virus vector-mediated expression of Bd-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc Natl Acad Sci USA 1999; 96(7):4078-4083. (Pubitemid 29169039)
150. Glorioso JC. Fink DJ. Use of HSV vectors to modify the nervous system. Curr Opin Drug Discov Devel 2002; 5(2):289-295. (Pubitemid 35012715)
151. Hong CS. Goins WF, Goss JR et al. Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer 's disease-related amyloid-beta peptide in vivo. Gene Ther 2006; 13(14) :1068-1079 .
152. Goss JR. Goins WF. Lacomis D et al. Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in srreptozorocin-induced diabetes in the mouse. Diabetes 2002; 51(7) :2227-2232. (Pubitemid 34729029)
153. Goss JR, Mata M. Goins WF et al. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther 2001; 8(7):551 ,556. (Pubitemid 32409530)
154. Marrino S. Marconi P. Tancini B et al. A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease. Hum Mol Genet 2005; 14(15):2113-2123. (Pubitemid 41418011)
155. Lanzi G. Ottolini A. Classification of neuromuscular diseases. Monaldi Arch Chcsr Dis 1993; 48(1):62-64. (Pubitemid 23155306)
156. Chao MY. Trophic faerors: An evolutionary cul-de-sac or door into higher neuronal function? J Neurosci Res 2000; 59(3):353-355.
157. Korsching S. The neurotrophic factor concept: a reexamination. J Neurosci 1993; 13(7):2739-2748 . (Pubitemid 23199204)
158. Marconi P, Zucchini S, Berro E et al, Effects of defective herpes simplex vectors expressing neurotrophic factors on the proliferation and differentiation of nervous cells in vivo. Gene Ther 2004.
159. Perez MC. Hunt SP, Coffin RS et al. Comparative analysis of genomic HSV vectors for gene delivery to motor neurons following peripheral inoculation in vivo. Gene Ther 2004; 11(13):1023-1032. (Pubitemid 39023106)
160. Palmer JA, Bransron RH, Lilley CE et al. Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system.J Virol 2000; 74(12):5604-5618. (Pubitemid 30346595)
161. Braz J, Beaufour C, Couraux A et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci 2001; 21(20) :7881-7888. (Pubitemid 32952747)
162. Liu X. Brandt CR, Gabelt BT et al. Herpes simplex virus mediated gene transfer to primate ocular tissues. Exp Eye Res 1999; 69(4) :385-395. (Pubitemid 29469906)
163. Spencer B. Agarwala S, Miskulin M et al. Herpes simplex virus-mediated gene delivery to the rodent visual system. Invest Ophthalmol Vis Sci 2000; 41(6):1392-1401. (Pubitemid 30261862)
164. Kuriyama S, Nakatani T. Masui K et al. Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. Hepatology 1995; 22(6): 1838-1846.
165. Vile RG, Han IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993; 53(17):3860-3864. (Pubitemid 23267677)
166. Chen CY. Chang YN. Ryan P et al. Effect of herpes simplex virus thymidine kinase expression levelson ganciclovir-mediared cytotoxicity and the "bystander effect".Hum Gene Ther 1995; 6(11):1467-1476.
167. Ram Z. Culver KW; Oshiro EM et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997; 3(12) :1354-1361. (Pubitemid 28011035)
168. Sandmair AM. Loimas S. Puranen P et al. Thymidine kinase gene therapy for human malignant glioma. using replication-deficient retroviruses or adenoviruses, Hum Gene Ther 2000 ; 11(16) :2197-2205.
169. Shalev M. Kadmon D. Teh BS et al. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 2000; 163(6):1747-1750. (Pubitemid 30366727)
170. Mileric H. Fischer Y, Litwak S et al. Bystander Killing of Malignant Glioma by Bone Marrow-derived Tumor-Infiltrating Progenitor Cells Expressing a Suicide Gene. Mol Ther 2007; 15(7):1373-1381. (Pubitemid 46965333)
171. Moolten FL. Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82(4) :297-300 . (Pubitemid 20097702)
172. Grandi P. Spear M. Breakeficld XO et al Targeting HSV arnplicon vectors. Methods 2004; 33(2):179-186.
173. Grandi P. Wang S. Schuback D et al. HSV-1 virions engineered for specific binding to cell surface receptors . Mol Ther 2004; 9(3):419-427. (Pubitemid 38404531)
174. Nakano K. Asano R. Tsumoto K et al. Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. Mol Ther 2005 ; 11(4):617-626 . (Pubitemid 40353119)
175. Shah K. Breakcficld XO. HSV amplicon vectors for cancer therapy. Curr Gene Ther. 2006; 6(3) :361-370. (Pubitemid 43905452)
176. Pin RH. Reinblatr M. Bowers WJ et al. Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma . J Gastrointest Surg 2004; 8(7 ):812-822; discussion 822-813.
177. Reinblatt M. Pin RH. Bowers WJ et al. Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-l) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma. Ann Surg Oncol 2005 ; 12(12):1025-1036. (Pubitemid 41660678)
178. Ziberr A. Thomassen A. Muller L et al. Herpes simplex virus type-I amplicon vectors for vaccine generation in acute lymphoblastic leukemia. Gene Ther 2005 ; 12(23):1707-1717. (Pubitemid 41679174)
179. Tolba KA. Bowers WJ. Muller J et al. Herpes simplex virus (HSV ) arnplicon-med iated codelivery of secondar y lymphoid tissue chemokine and CD40L results in augmented anti-tumor activity. Cancer Res 2002 ; 62(22 ):6545-6551. (Pubitemid 35364120)
180. Mizuno H. Yanoma S. Nishimura G et al, Therapeutic efficiency of IL-2 gene transduced tumor vaccine for head and neck carcinoma . Cancer Lett 2000 ; 152(2):175-185. (Pubitemid 30201500)
181. Herrlinger U. Jacobs A. Qnones A et al. Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therap y for experimental glioma. Hum Gene Ther 2000 ; 11(10) :1429-1438 . (Pubitemid 30451023)
182. Lu PY. Xie F. Woodle MC. In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 2005; 54:117-142.
183. Chen CZ . MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005; 353(17):1768-1771.
184. Saydam O. Glauser DL. Heid I et al. Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. Mol Ther 2005 ; 12(5):803-812. (Pubitemid 41614475)
185. Sabbioni S. Callegari E. Manservigi M et al. Use of herpes simplex virus type I-based amplicon vector for delivery of small inte rfering RNA. Gene Ther 2007; 14(5):459-46 4.
186. Aghi M. Kramm CM. Chou TC et al. Synergistic anti-cancer effects of ganciclovir/thymidine kinase and 5-Auorocytosine/c ytosine deaminase gene therapies. J Natl Cancer Inst 1998; 90(5 ):370-380. (Pubitemid 28131005)
187. Aghi M. Hochberg F. Breakefield XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med 2000 ; 2(3):148-164 .
188. Wang S. Qi J. Smith M et al. Antitumor effects on human melanoma xenografis of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovir. Cancer Gene Ther 2002; 9(1) :1-8. (Pubitemid 34052848)
189. Rainov NG. Dobberstein KU. Serra-Esteves M et al. New prodrug activation gene therapy for cancer using cytochrome P450 4Bl and 2-aminoanthracene/4- ipomeanol. Hum Gene Ther 1998; 9(9) :1261-1273. (Pubitemid 28312891)
190. Jacobs AH. Rueger MA. Winkeler A et al. Imaging-guided gene therapy of experimental gliomas. Cancer Res 2007; 67(4):1706-1715. (Pubitemid 46383397)
191. Jacobs AH . Winkeler A. Hartung M et al. Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. Hum Gene Ther 2003 ; 14(3):277-297. (Pubitemid 36423446)
192. Hoffmann D. Wildner O. Comparison of herpes simplex virus- and conditionally replicative adenovirus- based vector s for glioblastoma treatment. Cancer Gene Ther 2007; 14(7):627-639. (Pubitemid 46912039)
193. Hoffmann D. Bangen JM. BayerW et al. Synergy between expression of fusogenic membrane proteins. chemotherapy and facultative virotherapy in colorectal cancer. Gene Ther 2006; 13(21):1534-1544. (Pubitemid 44567150)
194. Lee CY, Bu LX. Rennie PS et al. An HSV-1 amplicon system for prostate-specific expression of lCP4 to complement oncolytic viral replication for in virro and in vivo treatment of prostate cancer cells. Cancer Gene Ther 2007; 14(7):652-660 . (Pubitemid 46912037)
195. Carew JF. Federoff H. Halterman M et al. Efficient gene transfer to human squamous cell carcinomas by the herpes simplex virus type 1 amplicon vector. Am J Surg 1998; 176(5):404-408. (Pubitemid 29021536)
196. Carew JF. Kooby DA. Halterman MW et al. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol Ther 2001: 4(3):250-256. (Pubitemid 32851289)
197. Wang GY,Ho IA,Sia KC et al.Engineering an improved cell cycle-regulatable herpes simplex virus Type 1 amplicon vector with enhanced transgene expression in proliferating cells yet altenuated activities in resting cells. Hum Gene Ther 2007:18(3):222-231. (Pubitemid 46626461)
198. Ho IA. Hui KM. Lam PY. Targeting proliferating tumor cells via the transcriptional control of therapeutic genes. Cancer Gene Ther 2006: 13(1):44-52. (Pubitemid 41816348)
199. Ho lA, Hui KM. Lam PY. Glioma-specific and cell cycle-regulated herpes simplex virus type 1 amplicon viral vector. Hum Gene Ther 2004; 15(5):495-508. (Pubitemid 38639620)
200. Lam PY, Sia KC. Khong JH et al.An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas.Mol Ther 2007; 15(6):1129-1136. (Pubitemid 46823025)
201. Shah K. Tung CH. Breakefield XO et al. In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Mol Ther 2005; 11(6):926-931. (Pubitemid 40724111)
202. Shah K. Tung CH. YangK et al. Inducible releaseofTRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Res 2004; 64(9):3236-3242. (Pubitemid 38581428)
203. Shah K. Tang Y, BreakefieldX et al. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 2003; 22(44) :6865-6872. (Pubitemid 37386686)
204. Raffaella R. Gioia D. De Andrea M et al. The interferon-inducible IFI16 gene inhibits tube morpho. genesis and proliferation of primary. but not HPV16 E6/E7-immorealized human endothelial cells.Exp Cell Res 2004; 293(2):331-345. (Pubitemid 38083223)
205. Niranjan A. Wolfe D. Tamura M et al. Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Mol Ther 2003: 8(4):530-542. (Pubitemid 37321681)
206. Berro E. Bozac A. Volpi I et al. Antitumor effects of nonreplicarive herpes simplex vectors expressing anti-angiogenic proteins and thymid ine kinase on Lewis lung carcinoma establishment and growth . Cancer Gene Ther 2007.
207. Berro E. Bozac A. Marconi P. Development and application of replication-incompetent HSV-1-based vectors. Gene Ther 2005; 12 Suppl 1:598-102.
208. Moriuchi S. Wolfe D. Tamura M et al, Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model Gene Ther 2002; 9(9) :584-591. (Pubitemid 34567775)
209. Moriuchi S. Krisky DM. Marconi PC et al.HSV vector cytoto xicity is inversely correlated with effective TKlGCV suicide gene therapy of rat g1iosarcoma. Gene Ther 2000; 7(17):1483-1490 .
210. Niranjan A. Moriuchi S. Lunsford LD et al. Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol Ther 2000: 2(2):114-120.
211. Marconi P, Tamura M. Moriuchi S et al. Connexin 43-enhanced suicide gene therapy using herpesviral vectors. Mol Ther 2000; 1(1):71-81.
212. Moriuchi S. Oligino T. Krisky D et al. Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coezpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Res 1998; 58(24):5 731-5737. (Pubitemid 29006414)
213. Advani SJ. Chung SM. Yan SY et al. Replication-competent. nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res 1999: 59(9):2055-2058. (Pubitemid 29217663)
214. Todo T. Rabkin SD. Sundaresan P et al. Systemic anti-tumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 1999; 10(17) :2741-2755.
215. Todo T. Feigenbaum F. Rabkin SD et al. Viral shedding and biodistribution of G207. a multimutated, conditionally replicating herpes simplex virus type 1. after intracerebral inoculation in aorus. Mol Ther 2000; 2(6) :588-595.
216. Toda M. Rabkin SD. Kojima H et al. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene 'Ther 1999; 10(3):385-393. (Pubitemid 29097317)
217. Mullen JT. Kasuya H. Yoon SS et al. Regulation of herpes simplex virus 1 replication using tumo rassociated promoters. Ann Surg 2002; 236(4):502-512: discussion 512-503.
218. Markert JM. Parker IN. Gillespie GY et al. Genetically engineered human herpes simplex virus in the treatment of brain tumours . Herpes 2001; 8(1):17-22. (Pubitemid 32290374)
219. Markert JM. Parker IN. Buchsbaum DJ et al. Oncolytic HSV-1 for the treatment of brain tumours. Herpes 2006; 13(3):66-71. (Pubitemid 44955374)
220. Galanis E. Vile R. Russell 5J. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol 2001: 38(3):177-192. (Pubitemid 32448027)
221. Marruza RL, Malick A, MarkertJM et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252(5007):854-856. (Pubitemid 121000529)
222. Jeyarema DS, Rabkin SD, Manuza RL. Oncolytic herpes simplex virus therapy for peripheral nerve tumors. Neurosurg Focus 2007; 22(6):E4.
223. Kramm CM, Chase M, Herrlinger U et al. Therapeutic efficiencyand safety of a second-generation replication- conditional HSVI vector for brain tumor gene therapy. Hum Gene Ther 1997; 8(17):2057-2068. (Pubitemid 28072576)
224. Dambach MJ, Trecki J, Martin N et al. Oncolytic viruses derived from the gamma34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein. Mol Ther 2006 ; 13(5) :891-898.
225. Cassady KA, Gross M, Roizman B. The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2a1pha.J Virol 1998; 72(9) :7005-7011. (Pubitemid 28377827)
226. Andreansky S, Soroceanu L, Flotte ER et al. Evaluation ofgenetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 1997; 57(8) :1502-1509. (Pubitemid 27175567)
227. Boviatsis EJ, Scharf JM, Chase M et al. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther 1994 1(5) 323-331.
228. Carroll NM, Chase M, Chiocca EA et al. The effect of ganciclovir on herpes simplex virus-mediated oncolysis.J Surg Res 1997; 69(2) :413-417. (Pubitemid 27317891)
229. Chambers R, Gillespie GY, Soroceanu L et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA 1995; 92(5):1411-1415.
230. Chou J, Roizman B. The herpes simplex virus 1 gene for 1CP34.5 which maps in inverted repeats is conserved in several limited-passage isolates but not in strain 17syn+.J Virol 1990, 64, 3, 1014-1020. (Pubitemid 20087735)
231. Liu BL, Robinson M, Han ZQ et al. 1CP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating and anti-tumour properties. Gene Ther 2003; 10(4) :292-303 . (Pubitemid 36305598)
232. Mineta T, Rabkin SD, Yazaki T et al. Attenuated multi-mutated herpes simplex virus-l for the treatment of malignant gliomas. Nat Med 1995; 1(9):938-943.
233. Hunter WD, Martuza RL, Feigenbaum F et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates.J Virol 1999; 73(8) :6319-6326. (Pubitemid 29327808)
234. Markert JM, Medlock MD, Rabkin SD et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000 ; 7(10) :867-874. (Pubitemid 30303584)
235. Rampling R, Cruickshank G, Papanastassiou V et al. Toxicity evaluation of replication-competent herpes simplex virus (rCp 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000 ; 7(10) :859-866. (Pubitemid 30303583)
236. Harrow S, Papanastassiou V, Harland J et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 2004.
237. Randazzo BP, Kucharczuk JC, Litzky LA et al. Herpes simplex 1716-an rcp 34.5 mutant-is severely replication restricted in human skin xenografis in vivo. Virology 1996: 223(2) :392-395. (Pubitemid 26319602)
238. Randazzo BP, Kesari S, Gesser RM et al. Treatment of experimental intracranial murine melanoma with a neuroartenuated herpes simplex virus 1 mutant. Virology 1995; 211(1) :94-101.
239. Kooby DA, Carew JF, Halterman MW et al. Oncolytic viral ther apy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-l (G207). FASEB J 1999 ; 13(11):1325-1334. (Pubitemid 29382501)
240. Cozzi PJ, Burke PB, Bhargav A et al. Oncolytic viral gene therapy for prostate cancer using two attenuated , replication-competent, genetically engineered herpes simplex viruses. Prostate 2002; 53(2) :95-100.
241. McAuliffe PF, Jarnagin WR, Johnson P et al. Effective treatment of pancreatic tumors with twO multimutated herpes simplex oncolytic viruses.J Gastro intest Surg 2000; 4(6) :580-588 .
242. Kasuya H, Takeda S, Nomoto S et al. The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther 2005 ; 12(9) :725-736. (Pubitemid 41208612)
243. Carew JF, Kooby DA, Halterman MW et al. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther 1999; 10(10) :1599-1606. (Pubitemid 29328204)
244. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents .J Infect Dis 1988; 158(3) :602-614.
245. Andreansky S, He B, van Cotr J et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins , Gene Ther 1998; 5(1) :121-130 . (Pubitemid 28045078)
246. Parker JN, Gillespie GY, Love CE et al. Engineered herpes simplex virus expressing lL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 2000; 97(5) :2208-2213 . (Pubitemid 30134047)
247. Wong RJ, Patel SG, Kim S et al. Cytokine gene transfer enhances herpes oncolyt ic therapy in murine squamous cell carcinom a. Hum Gene Ther 2001: 12(3):253-265 . (Pubitemid 32163897)
248. Todo T. Manuza RL., Dallman MJ et al. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent anti-tumor immunity. Cancer Res 2001; 61(1):153-161. (Pubitemid 32095713)
249. Nakamura H. Mullen JT; Chandrasekhar S et al. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intrarumoral conversion of 5-lIuorocytosine to 5-lIuorouracil. Cancer Res 2001; 61(14) :5447-5452. (Pubitemid 32694925)
250. Pawlik TM. Nakamura H. Mullen JT et al. Prodrug bioact ivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 2002; 95(5) :1171-1181. (Pubitemid 34925371)
251. Aghi M. Chou TC. Suling K et al. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2Bl and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 1999; 59(16) :3861-3865. (Pubitemid 29393540)
252. Mohr I. Sternberg D. Ward S et al. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severelyattenuated in animals. J Virol 2001 ; 75(11) :5189-5196. (Pubitemid 32448541)
253. He B. Chou J. Brandimarti R et al. Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 1997; 71(8) :6049-6054. (Pubitemid 27304944)
254. Taneja S. MacGregor J, Markus S et al. Enhanced anti-tumor efficacyof a herpes simplex virus mutantisolated by genetic selection in cancer cells. Proc Natl Acad Sci USA 2001; 98(15):8804-8808. (Pubitemid 32678108)
255. Jorgensen TJ. Katz S. Wittmack EK et al. Ionizing radiation does not alter the anti-rumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia 2001; 3(5):451-456. (Pubitemid 32988816)
256. Nakamori M. Fu X. Pettaway CA et al. Potent anti-tumor activity alter systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 2004; 60(1) :53-60. (Pubitemid 38669229)
257. Fu X. Tao L. Jin A et al. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral anti-tumor effect. Mol Ther 2003; 7(6) :748-754. (Pubitemid 36790251)
258. Bennett DL. Boucher TJ. Armanini MP et al. The glial cell line-derived neurotrophic factor family receptor components are differentially regulated within sensory neurons alter nerve injury. J Neurosci 2000; 20(1) :427-437. (Pubitemid 30220528)
259. Martino G. Poliani PL. Furlan R et al. Cytokine therapy in immune-mediated demyelinating diseasesof the central nervous system: a novel gene therapy approach. J Neuroimmunol 2000; 107(2):184-190 . (Pubitemid 30347426)
260. Wade-Martins R. Saeki Y, Chiocca EA. Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther 2003, 7(5 Pt 1):604-612. (Pubitemid 36626240)
261. Wade-Martins R. White RE. Kimura H et al. Stable correction of a genetic deficiency in human cells by an episome carrying a 115 kb genomic eransgene. Nat Biotechnol 2000, 18(12):1311-1314.
262. Anderson DB. Laquerre S. Ghosh K et al. Pseudotyping of glycoprotein Dvdeficienr herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J Virol 2000, 74(5) :2481-2487. (Pubitemid 30091509)
263. Zhou G. Roizman B. Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci USA 2006, 103(14):5508-5513.
264. Zhou G. Roizman B. Separationof receptor-binding and profusogenicdomains of glycoproteinD of herpes simplex virus 1 into distinct interacting proteins. Proc Natl Acad Sci USA 2007; 104(10) :4142-4146. (Pubitemid 47181592)